AU2010220262B2 - Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (ZAK) - Google Patents

Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (ZAK) Download PDF

Info

Publication number
AU2010220262B2
AU2010220262B2 AU2010220262A AU2010220262A AU2010220262B2 AU 2010220262 B2 AU2010220262 B2 AU 2010220262B2 AU 2010220262 A AU2010220262 A AU 2010220262A AU 2010220262 A AU2010220262 A AU 2010220262A AU 2010220262 B2 AU2010220262 B2 AU 2010220262B2
Authority
AU
Australia
Prior art keywords
zak
disorders mediated
lower alkyl
treatment
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010220262A
Other languages
English (en)
Other versions
AU2010220262A1 (en
Inventor
Doriano Fabbro
Paul W. Manley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010220262A1 publication Critical patent/AU2010220262A1/en
Application granted granted Critical
Publication of AU2010220262B2 publication Critical patent/AU2010220262B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2010220262A 2009-03-06 2010-03-05 Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (ZAK) Ceased AU2010220262B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09154507 2009-03-06
EP09154507.9 2009-03-06
EP09166437.5 2009-07-27
EP09166437 2009-07-27
PCT/EP2010/052797 WO2010100248A1 (en) 2009-03-06 2010-03-05 Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)

Publications (2)

Publication Number Publication Date
AU2010220262A1 AU2010220262A1 (en) 2011-09-08
AU2010220262B2 true AU2010220262B2 (en) 2014-01-09

Family

ID=42115422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010220262A Ceased AU2010220262B2 (en) 2009-03-06 2010-03-05 Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (ZAK)

Country Status (11)

Country Link
US (1) US20120015968A1 (enExample)
EP (1) EP2403492A1 (enExample)
JP (1) JP2012519668A (enExample)
KR (1) KR20110132439A (enExample)
CN (1) CN102341102A (enExample)
AU (1) AU2010220262B2 (enExample)
BR (1) BRPI1013366A2 (enExample)
CA (1) CA2753637A1 (enExample)
MX (1) MX2011009310A (enExample)
RU (1) RU2011140404A (enExample)
WO (1) WO2010100248A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6697311B2 (ja) * 2016-04-01 2020-05-20 ショーワグローブ株式会社 手袋
CN108117553B (zh) * 2016-11-30 2019-08-16 暨南大学 炔苯基苯磺酰胺类选择性zak抑制剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US20080234285A1 (en) * 2004-01-22 2008-09-25 David Louis Feldman Combination of Organic Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
CN100343237C (zh) 2002-06-28 2007-10-17 日本新药株式会社 酰胺衍生物及医药品
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2005118833A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CN101282728A (zh) * 2005-08-11 2008-10-08 诺瓦提斯公司 有机化合物的组合
EA200970447A1 (ru) * 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
CN101185627B (zh) * 2007-12-14 2011-04-20 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼罗替尼缓释植入剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234285A1 (en) * 2004-01-22 2008-09-25 David Louis Feldman Combination of Organic Compounds
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHU et al. Gynecologic Oncology. 2008. 108(1): 182-190 *

Also Published As

Publication number Publication date
CA2753637A1 (en) 2010-09-10
JP2012519668A (ja) 2012-08-30
RU2011140404A (ru) 2013-04-20
MX2011009310A (es) 2011-10-13
EP2403492A1 (en) 2012-01-11
AU2010220262A1 (en) 2011-09-08
BRPI1013366A2 (pt) 2016-03-29
KR20110132439A (ko) 2011-12-07
US20120015968A1 (en) 2012-01-19
CN102341102A (zh) 2012-02-01
WO2010100248A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
Yokoshiki et al. Inhibition of L-type calcium current in rat ventricular cells by the tyrosine kinase inhibitor, genistein and its inactive analog, daidzein
EP1250140B1 (en) Combination ofan abl-, pdgf-receptor- and/or kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to alpha1-acidic glycoprotein
AU2016216636B2 (en) Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
US8569305B2 (en) Treatment of tuberous sclerosis associated neoplasms
US20140073660A1 (en) Pyrimidylaminobenzamide Derivatives for Treatment of Neurofibromatosis
CA2075346A1 (en) Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
AU2010220262A1 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (ZAK)
RU2481840C2 (ru) КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ А) ПИРИМИДИЛАМИНОБЕНЗАМИД И Б) ИНГИБИТОР КИНАЗЫ Thr315lle
RU2415672C2 (ru) Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
EP2186514B1 (en) Treatment of Malignant Peripheral Nerve Sheath Tumors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired